Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 16/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22369098 | 0.81 | OPRK1 (0.32) | OPRK1ABL1CNR2 | |
| SCHEMBL26023823 | 0.77 | DGAT1 (0.36) | OPRK1ABL1ALDH1A1 | |
| SCHEMBL1516793 | 0.77 | NAPRT (0.46) | OPRK1ALDH1A1 | |
| SCHEMBL29498804 | 0.77 | NAPRT (0.46) | OPRK1ALDH1A1 | |
| SCHEMBL20504270 | 0.77 | CCR1 (0.36) | OPRK1ABL1 | |
| SCHEMBL25335179 | 0.75 | DGAT1 (0.52) | ALDH1A1 | |
| SCHEMBL21815554 | 0.75 | ALDH1A1 (0.35) | OPRK1ALDH1A1 | |
| SCHEMBL9648890 | 0.75 | OPRK1 (0.42) | OPRK1ALDH1A1TSHR | |
| SCHEMBL31356591 | 0.75 | OPRK1 (0.42) | OPRK1ALDH1A1TSHR | |
| SCHEMBL18050754 | 0.75 | HSP90AB1 (0.36) | OPRK1ALDH1A1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204360-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10206931-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10206931-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| WO-2016055028-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, CREBBP, HDAC1 | OPRK1 2898/4885ABL1 390/4885ALDH1A1 1533/4885 |
| US-10206931-B2 | Therapeutic compounds and uses thereof | EP300, CREBBP, HDAC1 | OPRK1 2898/4885ABL1 390/4885ALDH1A1 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.